Literature DB >> 24283361

Association between seven common OPG genetic polymorphisms and osteoporosis risk: a meta-analysis.

Liang Guo1, Ke Tang, Zhengxue Quan, Zenghui Zhao, Dianming Jiang.   

Abstract

Functional polymorphisms of the osteoprotegerin (OPG) gene are known to be involved in bone mineral density and the development of osteoporosis; however, some conflicting results have been reported. The aim of this meta-analysis is to provide a relatively comprehensive assessment of the relationship between seven common OPG genetic polymorphisms (T149C, A163G, G209A, T245G, T950C, G1181C, and C1217T) and osteoporosis risk. A literature search for eligible studies published before August 1st, 2013 was conducted in PubMed, Embase, Web of Science, Cochrane Library, and CNKI (China National Knowledge Infrastructure) databases. Pooled odds ratios and their corresponding 95% confidence intervals were used to evaluate the strength of the association under fixed- or random-effect models according to a heterogeneity test. All analyses were performed using the STATA software, version 12.0. Fourteen case-control studies with a total of 2383 osteoporosis cases and 2280 healthy controls were included in this meta-analysis. Among the seven polymorphisms, A163G and G1181C revealed significant associations with osteoporosis risk. For A163G (rs3102735), the combined results showed that the G allele of the A163G polymorphism may be associated with an increased risk of osteoporosis. Stratified analyses showed that the magnitude of the effect was similar in Caucasian and postmenopausal woman subgroups. For G1181C (rs2073618), however, we found that individuals with the C allele of the G1181C polymorphism had a decreased risk of osteoporosis, especially in Asian and postmenopausal woman subgroups. In summary, this meta-analysis indicated that the G allele of the OPG A163G polymorphism might increase osteoporosis risk in Caucasians, whereas individuals with the C allele of the G1181C polymorphism had a decreased risk of osteoporosis, especially in Asians. Both of these effects were observed in postmenopausal women. These polymorphisms could probably be used with other genetic markers together to identify individuals at a high risk of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24283361     DOI: 10.1089/dna.2013.2206

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  13 in total

1.  METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-κB signaling pathway.

Authors:  Jian Huang; Yi-Hsiang Hsu; Maxrco Brotto; David Karasik; Chenglin Mo; Eduardo Abreu; Douglas P Kiel; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

2.  Relationship between A163G osteoprotegerin gene polymorphism and other osteoporosis parameters in Roma and non-Roma postmenopausal women in eastern Slovakia.

Authors:  Marta Mydlárová Blaščáková; Ľudmila Blaščáková; Janka Poráčová; Jozef Mydlár; Janka Vašková; Jarmila Bernasovská; Iveta Boroňová; Eva Petrejčíková; Ivan Bernasovský
Journal:  J Clin Lab Anal       Date:  2016-11-15       Impact factor: 2.352

3.  Association of lactase 13910 C/T polymorphism with bone mineral density and fracture risk: a meta-analysis.

Authors:  Yougen Wu; Yinghua Li; Yunqing Cui; Yunjiao Zhou; Qingqing Qian; Yang Hong
Journal:  J Genet       Date:  2017-12       Impact factor: 1.166

4.  TNFRSF11B gene polymorphisms, bone mineral density, and fractures in Slovak postmenopausal women.

Authors:  Iveta Boroňová; Jarmila Bernasovská; Soňa Mačeková; Eva Petrejčíková; Zlatica Tomková; Ján Kľoc; Janka Poráčová; Marta Mydlárová Blaščáková; Eva Litavcová
Journal:  J Appl Genet       Date:  2014-10-17       Impact factor: 3.240

5.  Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH).

Authors:  R M R Pereira; C P Figueiredo; C C Cha; V F Caparbo; R M Oliveira; A S Franco; P R Menezes; I de Castro; L F Onuchic
Journal:  Osteoporos Int       Date:  2016-06-16       Impact factor: 4.507

6.  Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran.

Authors:  Mohammad Hashemi; Mahboubeh Ebrahimi; Shadi Amininia; Majid Naderi; Ebrahim Eskandari-Nasab; Mohsen Taheri
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014-10-01

7.  Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.

Authors:  Iwona Krela-Kaźmierczak; Marta Kaczmarek-Ryś; Aleksandra Szymczak; Michał Michalak; Marzena Skrzypczak-Zielińska; Natalia Drwęska-Matelska; Michalina Marcinkowska; Piotr Eder; Lilianna Łykowska-Szuber; Ewa Wysocka; Krzysztof Linke; Ryszard Słomski
Journal:  Calcif Tissue Int       Date:  2016-09-17       Impact factor: 4.333

8.  Association between osteoprotegerin gene T950C polymorphism and osteoporosis risk in the Chinese population: Evidence via meta-analysis.

Authors:  Shouyi Li; Huiqiang Jiang; Ningke Du
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

9.  Polymorphism rs2073618 of the TNFRSF11B (OPG) Gene and Bone Mineral Density in Mexican Women with Rheumatoid Arthritis.

Authors:  C A Nava-Valdivia; A M Saldaña-Cruz; E G Corona-Sanchez; J D Murillo-Vazquez; M C Moran-Moguel; M Salazar-Paramo; E E Perez-Guerrero; M L Vazquez-Villegas; D Bonilla-Lara; A D Rocha-Muñoz; B T Martín-Marquez; F Sandoval-Garcia; E A Martínez-García; N S Fajardo-Robledo; J M Ponce-Guarneros; M Ramirez-Villafaña; M F Alcaraz-Lopez; L Gonzalez-Lopez; J I Gamez-Nava
Journal:  J Immunol Res       Date:  2017-07-05       Impact factor: 4.818

10.  Experimental research into the potential therapeutic effect of GYY4137 on Ovariectomy-induced osteoporosis.

Authors:  Zhong-Shi Xu; Feng Dai; Ji Chen; Meng Lv; Ji-Wu Cheng; Xiao-Ming Zhang; Bo-Wen Lin
Journal:  Cell Mol Biol Lett       Date:  2018-10-01       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.